Key Deals This Week: Howard Hughes, Shift4 Payments, Herc Holdings, Celsius and More
Acelyrin (SLRN) Stock Surges After Unsolicited Buyout Proposal
Acelyrin Stock Jumps on Concentra Acquisition Interest
Reported Earlier, ACELYRIN Confirms Unsolicited $3/Share Offer From Concentra Biosciences Amid Pending Alumis Merger
Express News | ACELYRIN Confirms Receipt of Unsolicited Indication of Interest From Concentra Biosciences
Express News | Tang Capital Management Reports 5.3% Stake in ACELYRIN as of 18TH Feb- SEC Filing
Express News | Tang Capital Management: On Behalf of Concentra Biosciences Submit Non-Binding Proposal to Acquire ACELYRIN for $3.00 per Share
Alumis And ACELYRIN's Merger Marks A New Era For Late-Stage Biopharma Advancements
Alumis and Acelyrin Sign Merger Agreement
Wells Fargo Maintains Acelyrin(SLRN.US) With Buy Rating
Piper Sandler Sticks to Their Buy Rating for ACELYRIN, INC. (SLRN)
ACELYRIN, INC. (SLRN) Receives a Buy From Wells Fargo
Shareholder Alert: Ademi & Fruchter LLP Investigates Whether ACELYRIN, INC. Is Obtaining a Fair Price for Its Public Shareholders
Alumis and ACELYRIN To Merge; ACELYRIN Stockholders To Get 0.4274 Alumis Shares Each; Post-Transaction Ownership Of Combined Compsny Alumis 55%, ACELYRIN 45%.
Express News | Alumis Inc: Alumis & ACELYRIN's Combined Pro Forma Cash Position of About $737 Mln as of Dec 31, 2024, Provides Runway Into 2027
ACELYRIN: Evaluation Underway of Development Plan for Lonigutamab to Confirm Differentiation in a Cap Efficient Manner >SLRN
Alumis and ACELYRIN to Merge in an All-Stock Transaction >ALMS SLRN
Express News | Alumis Inc: Combined Company Will Operate Under Alumis Name With Current Alumis Executive Team
Express News | Alumis Inc: Alumis & ACELYRIN Stockholders to Own About 55% & About 45%, Respectively, of Combined Co on Fully Diluted Basis
Acelyrin Inc Trading Halted, News Pending